ASLAN Pharmaceuticals Announces 20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional 80M
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
ASLAN to receive 20 million in financing with the potential to receive up to an additional 80 million for an aggregate of 100 million to continue...
Read at globenewswire.com
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
NAMS | NewAmsterdam Pharma | 41.41 | ||||
ACRV | Acrivon Therapeutics, | 8.45 | ||||
CMPX | Compass Therapeutics | 7.88 | ||||
LYRA | Lyra Therapeutics | 5.00 | ||||
ANTX | AN2 Therapeutics | 2.65 | ||||
ANEB | Anebulo Pharmaceuticals | 0.64 | ||||
CGEM | Cullinan Oncology | 0.24 | ||||
IVA | Inventiva | 0.38 | ||||
ERAS | Erasca | 0.67 | ||||
GPCR | Structure Therapeutics | 1.30 | ||||
MLYS | Mineralys Therapeutics, | 1.45 | ||||
AVTE | Aerovate Therapeutics | 1.54 | ||||
CTMX | CytomX Therapeutics | 2.48 | ||||
ACHL | Achilles Therapeutics | 2.86 | ||||
IOBT | IO Biotech | 4.55 | ||||
AGIO | Agios Pharm | 5.76 | ||||
ASMB | Assembly Biosciences | 6.46 | ||||
TIL | Instil Bio | 7.12 | ||||
GLUE | Monte Rosa | 9.85 | ||||
ADAG | Adagene | 16.21 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |